DiaMedica has enrolled the first patient in the Phase II proof of concept clinical trial of DM-83 for the treatment of type 2 diabetes.
Subscribe to our email newsletter
Karl-Gunnar Hidinger, company’s president said that the single-blind trial will demonstrate DM-83’s level of effectiveness in controlling the blood glucose levels in twenty type 2 diabetics after they have consumed a meal. Changes in insulin and glucose levels are the study’s primary endpoints. Each patient will test both the effects of DM-83 as well as a placebo and therefore serve as their own control in this crossover study. Treatment will be concluded in the second quarter and results will be analyzed and released shortly thereafter. The results of this trial will be used to optimize the design of the next stage of clinical development for DM-83.
Mr Hidinger, said: “We have discovered a very unique approach to treating this disease and believe we have found something quite important, as indicated by the clinical growth of our drug pipeline over the past six months.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.